TCGA-E2-A14Z-01A-11R-A115-07
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
- overall_survival_months
- 19
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.580
- INTERFERON_ALPHA_RESPONSE+0.450
- INTERFERON_GAMMA_RESPONSE+0.450
- IL6_JAK_STAT3_SIGNALING+0.410
- INFLAMMATORY_RESPONSE+0.400
- PANCREAS_BETA_CELLS+0.290
- TNFA_SIGNALING_VIA_NFKB+0.290
- COAGULATION+0.240
- COMPLEMENT+0.240
- IL2_STAT5_SIGNALING+0.230
Top 10 suppressed
- ANDROGEN_RESPONSE-0.330
- NOTCH_SIGNALING-0.320
- MITOTIC_SPINDLE-0.300
- PROTEIN_SECRETION-0.290
- CHOLESTEROL_HOMEOSTASIS-0.250
- G2M_CHECKPOINT-0.220
- TGF_BETA_SIGNALING-0.190
- GLYCOLYSIS-0.170
- UV_RESPONSE_DN-0.170
- PI3K_AKT_MTOR_SIGNALING-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CV-A45T-01A-11R-A24H-07 | — | — | 0.829 |
| 2 | 0ec02d90-7ccb-476e-a8bb-9a9c8f158dee | — | — | 0.827 |
| 3 | SRR8518196 | — | D | 0.816 |
| 4 | f5760366-59eb-417d-a935-3f78e999dd42 | — | — | 0.809 |
| 5 | aa5bae83-33a0-4b75-a52d-7ba53267f6d3 | — | — | 0.806 |
| 6 | TCGA-BH-A2L8-01A-11R-A18M-07 | — | A | 0.802 |
| 7 | ad2bbb19-6d02-480f-b011-d4327c3c5607 | — | — | 0.800 |
| 8 | TCGA-LL-A5YO-01A-21R-A28M-07 | — | D | 0.798 |
| 9 | SRR2932829 | — | — | 0.790 |
| 10 | TCGA-E2-A1B5-01A-21R-A12P-07 | — | D | 0.784 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.580 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.450 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.450 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.410 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.290 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.290 | Inavolisib | — uncovered |
| COAGULATION | 0.240 | Binimetinib | — uncovered |
| COMPLEMENT | 0.240 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.230 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.220 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.160 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.160 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.130 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.110 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.110 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.090 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.080 | Inavolisib | — uncovered |
| APOPTOSIS | 0.070 | Idelalisib | — uncovered |